2[1]Wiser W,Berger A.Practical management of chemotherapy-induced nausea and vomiting.Oncology Williston Park),2005,19:637
3[2]Aapro M,et al.Palonosetron is effective in preventing acute and delayed chemotherapy-induced nausea and vomiting in patients recieving highly emetogenic chemotherapy (HEC)[Abstract].Support Care Cancer,2003,11:A17
4[3]Jordan K,Kasper C,Schmoll HJ.Chemotherapy-induced nausea and vomiting:Current and new standards in the antiemetic prophylaxis and treatment.Eur J Cancer,2005,41:199
5[4]Roila F,Donati D,Tamberi S,et al.Delayed emesis:Incidence,pattern,prognostic factors and optimal treatment.Support Care Cancer,2002,10:88
6[5]website:http//www.mascc.org.Multinational association for supportive care in cancer.Consensus Conference on antiemitic therapy Perugia,2004,March 29-31
7[6]Hesketh PJ,Kris MG,Grunberg SM,et al.Proposal for classifying the acute emetogenicity of cancer chemotherapy.J Clin Oncol,1997,15:103
8[7]Morrow GR.The effect of a susceptibility to motion sickness on the side effects of cancer chemotherapy.Cancer,1985,55:2766
9[8]Osoba D,Zee B,Pater J,et al.Determinants of postchemotherapy nausea and vomiting in patients with cancer.Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group.J Clin Oncol,1997,15:116
10[9]Doherty KM.Closing the gap in prophylactic antiemetic therapy:Patient factors in calculating the emetogenic potential of chemotherapy.Clin J Oncol Nurs,1999,3:113
5Navari RM, Einhom LH, Loehrer PJ Sr, et al. A phase Ⅱ trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group study [J]. Support Care Cancer, 2007, 15(11): 1285-1291.
6Common Terminology Criteria for Adverse Events(CT- CAE) Version 4.0. http://evs.nci.nih.gov/ftpl/CTCAE/CT- CAE 4.03 2010-06-14_QuickReference_5x7.pdf.
7Singhal AK, Kannan S, Gota VS. 5HT3 antagonists for prophylaxis of postoperative nausea and vomiting in breast surgery: a meta-analysis[J]. J Postgrad Med, 2012, 58(1): 23-31.
8Rojas C, Slusher BS. Pharmacological mechanisms of 5- HT3 and tachykinin NK receptor antagonism to prevent chemotherapy-induced nausea and vomiting [J]. Eur J Pharmacol, 2012, 684(1-3): 1-7.
9Passik SD, Navari RM, Jung SH, et al. A phase Ⅰ trial of olanzapine (Zyprexa) for the prevention of delayed emesis in cancer patients: a Hoosier Oncology Group study[J]. Cancer Invest, 2004, 22(3): 383-388.
10Navari RM, Einhom LH, Passik SD, et al. A phase Ⅱ trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier Oncology Group study[J]. Support Care Cancer, 2005, 13(7): 529- 534.
